1. AB0438 Efficacy and Safety of Tabalumab, an Anti-B Cell Activating Factor Monoclonal Antibody, in Patients with Rheumatoid Arthritis WHO HAD an Inadequate Response to Tnf-Alpha Inhibitors: Results from A Phase 3 Multicenter, Randomized, Double-Blind Study. (10th June 2014) Authors: Schiff, M.; Combe, B.; Dörner, T.; Kremer, J.M.; Huizinga, T.W.; Veenhuizen, M.; Gill, A.; Zou, H.; Komocsar, W.; Berclaz, P.-Y.; Ortmann, R.; Lee, C. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 952 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FRI0326 Efficacy and Safety of Tabalumab, an Anti-B Cell Activating Factor Monoclonal Antibody, in Patients with Rheumatoid Arthritis Who HAD an Inadequate Response to Methotrexate Therapy: Results from A Phase 3 Multicenter, Randomized, Double-Blind Study. (10th June 2014) Authors: Smolen, J.S.; Weinblatt, M.E.; van der Heijde, D.; Rigby, W.F.; van Vollenhoven, R.; Bingham, C.O.; Veenhuizen, M.; Gill, A.; Zou, H.; Komocsar, W.; Berclaz, P.-Y.; Ortmann, R.; Lee, C. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 504 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. OP0184 Efficacy and Safety of Tabalumab in Patients with Systemic Lupus Erythematosus (SLE): Results from 2 Phase 3, 52-Week, Multicenter, Randomized, Placebo-Controlled Trials. (9th June 2015) Authors: Isenberg, D.; Merrill, J.; Hoffman, R.; Linnik, M.; Morgan-Cox, M.; Veenhuizen, M.; Iikuni, N.; Dickson, C.; Silk, M.; Wallace, D.; Dörner, T. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 141 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗